Research prototype, not medical advice.

AMX0035 slowed functional decline in ALS in phase 2, but phase 3 (PHOENIX) was negative and it was withdrawn from the market in 2024.

Confidence
Debated
Level of evidence
Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Loss of proteostasisAMX0035 (phenylbutyrate + taurursodiol)Amyotrophic lateral sclerosis (ALS)

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Paganoni et al. · New England Journal of Medicine 2020
— Verified